Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases

Table 2

First-line therapy options applied.

Therapeutic regimen	Entire cohort (n = 110) n (%)	NET G1 and G2 (n = 75) n (%)	NEC G3 (n = 26) n (%)
Surgical resection	62 (56)	44 (59)	11 (42)
Without systemic therapy	47 (43)	34 (45)	7 (27)
Followed by SSA	11 (10)	10 (13)	0 (0)
Followed by chemotherapy	4 (4)	0 (0)	4 (15)
Chemotherapy	19 (17)	8 (11)	11 (42)
PRRT	21 (19)	17 (23)	2 (8)
Without systemic therapy	11 (10)	9 (12)	1 (4)
Followed by SSA	10 (9)	8 (11)	1 (4)
SSA	7 (6)	6 (8)	1 (4)
No therapy	1 (1)	0 (0)	1 (4)